A multi-centre, post-marketing surveillance study of Vi polysaccharide–tetanus toxoid conjugate vaccine (Typbar TCV®) in India

A typhoid Vi capsular-polysaccharide tetanus toxoid conjugate vaccine (Typbar-TCV®) was recommended by the World Health Organization for use in children >6 months of age. The present post-marketing surveillance study was intended to assess the clinical safety of approximately 11 million doses of...

Descripción completa

Detalles Bibliográficos
Autores principales: Reddy, Raghu, Reddy, Bhargav, Sarangi, Vamshi, Reddy, Siddharth, Ella, Raches, Vadrevu, Krishna Mohan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Licensed Vaccines – Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920194/
https://www.ncbi.nlm.nih.gov/pubmed/34242128
http://dx.doi.org/10.1080/21645515.2021.1947761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920194/
https://www.ncbi.nlm.nih.gov/pubmed/34242128
http://dx.doi.org/10.1080/21645515.2021.1947761

Ejemplares similares